HC Wainwright restated their buy rating on shares of Evofem Biosciences (NASDAQ:EVFM) in a report published on Monday morning, The Fly reports. They currently have a $12.50 target price on the biotechnology company’s stock.
Other research analysts have also issued research reports about the company. Cantor Fitzgerald reaffirmed an overweight rating on shares of Evofem Biosciences in a research report on Friday, November 23rd. ValuEngine lowered Evofem Biosciences from a buy rating to a hold rating in a report on Friday, December 21st. Finally, Oppenheimer set a $9.00 target price on Evofem Biosciences and gave the stock a buy rating in a report on Friday, November 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Evofem Biosciences has an average rating of Buy and an average price target of $10.70.
NASDAQ:EVFM opened at $3.86 on Monday. Evofem Biosciences has a twelve month low of $1.79 and a twelve month high of $12.56.
Several hedge funds have recently bought and sold shares of the stock. Millennium Management LLC increased its holdings in shares of Evofem Biosciences by 6,497.4% during the 2nd quarter. Millennium Management LLC now owns 733,765 shares of the biotechnology company’s stock worth $1,989,000 after acquiring an additional 722,643 shares during the last quarter. Heartland Advisors Inc. acquired a new position in shares of Evofem Biosciences during the 3rd quarter worth approximately $1,319,000. Vanguard Group Inc. acquired a new position in shares of Evofem Biosciences during the 3rd quarter worth approximately $879,000. Finally, Vanguard Group Inc acquired a new position in shares of Evofem Biosciences during the 3rd quarter worth approximately $879,000. 77.81% of the stock is currently owned by institutional investors and hedge funds.
About Evofem Biosciences
Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women.
Featured Story: Why are analyst ratings important in trading stocks?
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.